30 October 2024 in L.O. Badalyan Neurological Journal
Introduction. Nephrocalcinosis (NC) is defined as the deposition of calcium oxalate or calcium phosphate in the intratubular lumen and/or kidney interstitium. Recent studies have reported that NC might be a specific sign of hereditary kidney diseases with various phenotypic manifestations. The rate of genetic mutation as a rule was higher in children with earlier onset and positive family history. Purpose. To study the causes, characterize the genotype and phenotype in Russian children with NC. Materials and methods. A single-center retrospective-prospective cohort study included 91 patient under the age of 18 years, 57 (62.6%) boys and 34 (37.4%) girls with bilateral NC. We analyzed the phenotype and kidney function in NC children classified into 3 groups according to etiology: 1) primary tubulopathies; 2) tubulopathies due to metabolic and endocrine disorders; 3) NC, unconfirmed by molecular genetic research. Results. Pathogenic nucleotide variants were identified in 51 (56%) children with a predominance in the genes CLCN5, CYP24A1, AGXT, HPRT1 described in patients with Dent disease (OMIM 300009), primary hyperoxaluria type 1 (OMIM 259900), idiopathic infantile hypercalcemia type 1 (OMIM 143880), Lesh–Nihan syndrome (OMIM 300322) respectively. The median age of detection of NC was 16 years, 4 [3.9; 52.2 months, among which 42 (46.1%) children were under the age of 1 year, 44 (48.4%) aged 1 to 10 years, 5 (5.5%) older than 10 years. Various bone deformities prevailed among the extrarenal manifestations (19 (20.4%)). Over 3 years of follow-up (n = 51) the average GFR changed from 102.5 ± 26.0 ml/min/1.73 m2 to 94.5 ± 21.9 ml/min/1.73 m2 (p = 0.002); over 5 years of follow-up (n = 31) from 104.7 ± 23.9 ml/min/1.73 m2 to 89.6 ± 25.1 ml/min/1.73 m2 (p = 0.002), that was statistically significant in the group of primary tubulopathies (p = 0.030; p = 0.002). At baseline, the average GFR value was lower in NC stages 2 and 3. Conclusion. Conducting a molecular genetic study in NC children, in addition to early diagnosis of diseases with variable renal prognosis and will also help to achieve effectiveness in the timely prescription of pathogenetic and symptomatic therapy.
9 August 2024 in Pediatria. Journal named after G.N. Speransky
Treatment tactics for patients with congenital nephrotic syndrome (CNS) varies from aggressive kinds, such as early nephrectomy, to conservative ones that include diuretic and nutritional support. The purpose of this research was to assess the effectiveness of conservative treatment of children with congenital and infantile nephrotic syndromes. Materials and methods used: a single-center retrospective study of 11 pediatric patients who had been manifested with NS within their first year of life and had required diuretic therapy, was conducted. The effectiveness of conservative therapy was assessed as preservation of the renal function according to glomerular filtration and satisfactory weight/height and height alone parameters’ dynamics that ensure the safety of kidney transplantation. Results: despite the molecular genetic study was conducted in all 250 children with NS, the described 11 have had verified pathogenic variants as follows: in the NPHS1 gene in 5 (45.5%, CI 16.8-76.6%), in the NPHS2 gene in another 5 (45.5%, CI 16.8-76.6%) and a single patient with none of a kind. It was revealed that despite the persistence of pronounced NS laboratory activity, the edema gradually disappeared against the background of conservative therapy, which in its turn had made it possible to refrain from early nephrectomy as well as to begin the renal replacement therapy over the age of 3 (4) y/o. 9 (81.8%, CI 48.2-97.7%) had satisfactory weight and height parameters at the age of 3 y/o. Only a single patient had undergone the early nephrectomy at the age of 4 months old, that was then followed by a successful kidney transplant at the age of 1 year and 4 months old, which, however, did not affect the then positive height prognosis. Conclusion: thus, reasonably selected conservative therapy for CNS can be effective against edematous syndrome and contribute to satisfactory weight/height growth parameters without early nephrectomy and, accordingly, the start of dialysis during the first year of life.
10 August 2023 in Pediatria. Journal named after G.N. Speransky
25 June 2019 in Pediatric pharmacology
Петлевые тубулопатии: синдром Барттера
7 September 2019 in Pediatric pharmacology
Дистальные тубулопатии. Синдром Лиддла
17 June 2022 in Pediatria. Journal named after G.N. Speransky
Atypical hemolytic-uremic syndrome (aHUS) is an orphan disease characterized by the development of thrombotic microdgium due to uncontrolled activation of the alternative complement pathway. Mutations of factors preventing excessive activation of the complement system are detected in most patients. For many years, despite the lack of appropriate evidence-based indications, plasmotherapy (PT) remained the first line treatment method. However, approaches to the management of patients have changed significantly with the accumulation of numerous data on the rapid progression to the end-stage renal disease regardless of whether PT was carried out initially or not. Statistical data has changed significantly with the launch of pathogenetic anticomplement therapy with monoclonal antibody (mAb) eculizumab due to most patients achieving remission of TMA and normalization of renal functions. The article presents a clinical case of a child with typical features of nephrotic syndrome with an early onset of disease. A heterozygous mutation in the CFH gene that was detected initially did not cause concerns about possible aHUS due to the lack of laboratory and morphological data for TMA. However, subsequently, the episodes of acute renal injury in combination with thrombotic microangiopathy (TMA) and severe arterial hypertension developed in a child, which made it possible to reconsider the diagnosis of aHUS and initiate the therapy with the biological analogue of eculizumab of a Russian origin, in which remission of TMA and complete recovery of renal functions were achieved. This clinical case demonstrates the difficulties of differential diagnosis of congenital nephropathies. Prognostic adverse outcomes in aHUS require a thorough evaluation of data with early induction of specific biological therapy, which allows the successful monitoring of the course of the disease.